Short answer
MeiraGTx Holdings plc (MGTX) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
MeiraGTx Holdings plc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Investor focus: review the accompanying press release for revenue, cash position, expenses and pipeline updates
Item EX-99.1 · Exhibit EX-99.1
- Bota-vec MAA submission targeted December 2026, with full FDA BLA expected Q1 2027 and potential commercial launch in late 2027
- Cash, equivalents and restricted cash $186.8M, with funding projected into H2 2028 including $95.0M Hologen payment and reimbursements
- Q3 revenue $4.8M, including $3.2M related-party service revenue, but net loss widened to $51.3M from $50.5M
- R&D spending increased to $39.3M from $32.5M, reflecting bota-vec, AAV2-hAQP1 and AAV-GAD development investment
- AQUAx2 enrollment completed, with pivotal 12-month data expected mid-2027 and potential BLA submission by end-2027 if positive
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MeiraGTx Holdings plc 8-K filings
Get the next MGTX 8-K as it lands
Follow MGTX for push alerts, or ask the research agent what this filing means.